PMID- 15121303
OWN - NLM
STAT- MEDLINE
DCOM- 20040618
LR  - 20071114
IS  - 0264-410X (Print)
IS  - 0264-410X (Linking)
VI  - 22
IP  - 15-16
DP  - 2004 May 7
TI  - Associations between human leukocyte antigen (HLA) alleles and very high levels 
      of measles antibody following vaccination.
PG  - 1914-20
AB  - Associations between human leukocyte antigen (HLA) genes and very high levels of 
      antibodies (or hyperseroresponsiveness) to measles antigens in a genetically 
      heterogeneous human population are poorly understood. We studied the association 
      between antibody levels after measles vaccination and HLA class I and II alleles 
      among 170 US schoolchildren who received one dose of measles-mumps-rubella II 
      vaccine. Vaccine recipients were divided into two groups: 93 recipients who were 
      seropositive and 77 recipients who were hyperseropositive (the upper 10th 
      percentile of antibody levels of all subjects). Out of all the alleles analyzed, 
      HLA-B(*)7 (odds ratio (OR) 1.9; P = 0.05), DQA1(*)0104 (OR 4.6; P = 0.02) and 
      DPA1(*)0202 (OR 4.8; P = 0.04) alleles were positively associated with 
      hyperseropositivity, whereas HLA-B(*)44 (OR 0.4; P = 0.02), DRB1(*)01 (OR 0.6; P 
      = 0.09), DRB1(*)08 (OR 0.3; P = 0.04), DQB1(*)0301 (OR 0.5; P = 0.04), and 
      DPB1(*)0401 (OR 0.6; P = 0.03) alleles were negatively associated with 
      hyperseropositivity. The alleles B(*)44, DRB1(*)01, DRB1(*)08 and DQA1(*)0104 
      remained statistically significant after accounting for the effects of other 
      alleles. The results suggest that HLA alleles have important associations with 
      measles antibody hyperseropositivity. These data increase our understanding of 
      measles vaccine-induced immune response and will be useful for future mechanistic 
      work on measles virus antigen processing and presentation in seronegative and 
      hyperseropositive individuals.
FAU - Ovsyannikova, Inna G
AU  - Ovsyannikova IG
AD  - Mayo Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Jacobson, Robert M
AU  - Jacobson RM
FAU - Vierkant, Robert A
AU  - Vierkant RA
FAU - Shane Pankratz, V
AU  - Shane Pankratz V
FAU - Jacobsen, Steven J
AU  - Jacobsen SJ
FAU - Poland, Gregory A
AU  - Poland GA
LA  - eng
GR  - M01-RR-00585-25/RR/NCRR NIH HHS/United States
GR  - N01-AI-45240/AI/NIAID NIH HHS/United States
GR  - R01-2AI-33144/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Antibodies, Viral)
RN  - 0 (HLA Antigens)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Measles Vaccine)
SB  - IM
MH  - Alleles
MH  - Antibodies, Viral/*analysis
MH  - Antibody Formation/immunology
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - HLA Antigens/*genetics
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunoglobulin G/analysis/biosynthesis
MH  - Logistic Models
MH  - Male
MH  - Measles Vaccine/*immunology
MH  - Vaccination
EDAT- 2004/05/04 05:00
MHDA- 2004/06/24 05:00
CRDT- 2004/05/04 05:00
PHST- 2003/06/10 00:00 [received]
PHST- 2003/11/06 00:00 [accepted]
PHST- 2004/05/04 05:00 [pubmed]
PHST- 2004/06/24 05:00 [medline]
PHST- 2004/05/04 05:00 [entrez]
AID - S0264410X03008089 [pii]
AID - 10.1016/j.vaccine.2003.11.016 [doi]
PST - ppublish
SO  - Vaccine. 2004 May 7;22(15-16):1914-20. doi: 10.1016/j.vaccine.2003.11.016.